The Sant Pau Research Institute announces the creation of the new research group in Advanced Medical Imaging, Artificial Intelligence, and Image-Guided Therapy. Dr. Josep Munuera, a researcher with a broad trajectory in the use of artificial intelligence applied to medicine and director of the Radiodiagnosis Service at Hospital Sant Pau, will lead this cross-sectional and multidisciplinary project that seeks to go beyond traditional specializations.
According to the results of an international study involving researchers from the Clinical Oncology group at the Sant Pau Research Institute, led by Dr. Teresa Ramon y Cajal, the follow-up with magnetic resonance imaging in women with mutations in the BRCA1 genes who have a high risk of developing breast cancer throughout their lives significantly reduces mortality without the need for preventive mastectomy.
L’Institut de Recerca Sant Pau (IR Sant Pau) i el Banc de Sang i Teixits (BST) han signat un acord de col·laboració destinat a impulsar el desenvolupament i la producció de medicaments innovadors.
L’acord, que representa una aliança pionera entre dues institucions capdavanteres en el camp de la salut, estableix les bases per a la creació d’un node conjunt que comptarà amb instal·lacions preparades per a la producció de teràpies avançades, incloent-hi les cèl·lules CAR-T.
A group of scientists from various hospitals and research centers in Catalonia, led by Drs. Álvaro Carbayo and Ricard Rojas, researchers from the Neuromuscular Diseases Group at the Sant Pau Research Institute, in collaboration with Dr. Sergi Borrego-Écija and Dr. Ellen Gelpi from the Alzheimer’s Disease and other Cognitive Disorders Group and the Neurological Tissue Bank of IDIBAPS, have published a study in the journal Brain that reveals connections between two devastating brain diseases: Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia.
The detection of phosphorylated TAU 217 protein (p-tau217) in plasma has shown high precision in identifying pathological accumulations of beta-amyloid and TAU proteins. This precision is comparable to traditional biomarker detection in cerebrospinal fluid, as revealed by a recent study published in JAMA Neurology. Researchers from the Research Area in Neurological Diseases, Neuroscience, and Mental Health at the Sant Pau Research Institute, led by Dr. Juan Fortea, Director Sof the Memory Unit at the Neurology Department of the same hospital, participated in the study. These results pave the way for diagnosing Alzheimer’s disease through a blood test.